[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100200324":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":29,"responsibleParty":43,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":10,"maxAge":55,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"PAH patients",null,"Patients diagnosed with WHO Group 1 PAH",{"label":13,"type":10,"description":14,"interventionNames":10},"Healthy subjects","Subjects who have been evaluated for heart and lung disease and found to be healthy",[16],{"name":17,"affiliation":5,"role":18},"James E Loyd, MD","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Kelly L Fox","CONTACT","800-288-0378","Kelly.Burke@vumc.org",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Shannon Cordell, BSN","615-343-8277","shannon.eason@vumc.org",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"RECRUITING","Nashville","Tennessee","37232","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-86.78444,36.16589,{"lat":41,"lon":40},{"type":18,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Anna Hemnes","Associate Professor of Medicine","100200324","hormonal-metabolic-and-signaling-interactions-in-pah-100200324",false,"NCT01884051","Hormonal, Metabolic, and Signaling Interactions in PAH","Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension","Inclusion Criteria:\n\nProject 1\n\nInclusion:\n\n1. Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons\n2. Age 0-90, age 12-90 for skin biopsy\n\nExclusion:\n\n1. Other diagnosis\n2. Age greater than 90, age less than 12 or greater than 90 for skin biopsy\n\nProject 2\n\nInclusion:\n\n1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons\n2. 0-90\n3. Subjects with reasonably easy access to clinic for blood collection and other testing\n4. Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing\n\nExclusion:\n\n1. Other diagnosis\n2. 0-90\n3. Subjects with difficulty reaching clinic for blood collection and other testing\n4. Subjects unable to tolerate fasting state\n\nProject 3\n\nInclusion:\n\n1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons\n2. 7-90\n\nExclusion:\n\n1. Other diagnosis\n2. Age less than 7 or greater than 90\n\n   \\-\n\n   Exclusion Criteria:\n\n   \\-",true,"ALL","90 Years",{"count":57,"type":58},1899,"ESTIMATED","OBSERVATIONAL","Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.",[62,63,64,65],"Idiopathic Pulmonary Arterial Hypertension","Heritable Pulmonary Arterial Hypertension","Scleroderma Associated Pulmonary Arterial Hypertension","Appetite Suppressant Associate PAH",[67],"Pulmonary arterial hypertension","2025-09-15",{"date":70,"type":71},"2025-09-16","ACTUAL",{"date":73,"type":10},"2012-09",{"date":75,"type":58},"2032-07",{"name":5,"class":6},1]